Johnson Investment Counsel’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $847K | Buy |
4,469
+147
| +3% | +$27.6K | 0.01% | 491 |
|
|
2026
Q1 | $852K | Sell |
4,322
-327
| -7% | -$63.1K | 0.01% | 465 |
|
|
2025
Q4 | $855K | Sell |
4,649
-62
| -1% | -$10.9K | 0.01% | 435 |
|
|
2025
Q3 | $723K | Sell |
4,711
-167
| -3% | -$25.3K | 0.01% | 490 |
|
|
2025
Q2 | $682K | Sell |
4,878
-76
| -2% | -$10.7K | 0.01% | 481 |
|
|
2025
Q1 | $728K | Buy |
4,954
+207
| +4% | +$29.9K | 0.01% | 457 |
|
|
2024
Q4 | $622K | Buy |
4,747
+1,416
| +43% | +$198K | 0.01% | 481 |
|
|
2024
Q3 | $519K | Sell |
3,331
-241
| -7% | -$38.9K | 0.01% | 511 |
|
|
2024
Q2 | $557K | Buy |
3,572
+354
| +11% | +$53.3K | 0.01% | 475 |
|
|
2024
Q1 | $436K | Sell |
3,218
-24
| -0.7% | -$3.18K | ﹤0.01% | 530 |
|
|
2023
Q4 | $437K | Buy |
3,242
+399
| +14% | +$51.9K | 0.01% | 507 |
|
|
2023
Q3 | $385K | Buy |
2,843
+334
| +13% | +$45.6K | 0.01% | 509 |
|
|
2023
Q2 | $359K | Buy |
2,509
+133
| +6% | +$19.6K | ﹤0.01% | 534 |
|
|
2023
Q1 | $330K | Sell |
2,376
-146
| -6% | -$19.6K | ﹤0.01% | 534 |
|
|
2022
Q4 | $342K | Buy |
2,522
+26
| +1% | +$3.26K | ﹤0.01% | 523 |
|
|
2022
Q3 | $274K | Sell |
2,496
-29
| -1% | -$3.68K | ﹤0.01% | 550 |
|
|
2022
Q2 | $334K | Sell |
2,525
-143
| -5% | -$18.8K | ﹤0.01% | 526 |
|
|
2022
Q1 | $354K | Sell |
2,668
-478
| -15% | -$57.3K | ﹤0.01% | 540 |
|
|
2021
Q4 | $366K | Sell |
3,146
-497
| -14% | -$58.5K | ﹤0.01% | 524 |
|
|
2021
Q3 | $438K | Buy |
3,643
+604
| +20% | +$70.3K | 0.01% | 475 |
|
|
2021
Q2 | $364K | Sell |
3,039
-336
| -10% | -$36.9K | 0.01% | 498 |
|
|
2021
Q1 | $336K | Sell |
3,375
-809
| -19% | -$81.3K | 0.01% | 489 |
|
|
2020
Q4 | $418K | Buy |
4,184
+690
| +20% | +$73.1K | 0.01% | 432 |
|
|
2020
Q3 | $383K | Buy |
3,494
+46
| +1% | +$5.12K | 0.01% | 424 |
|
|
2020
Q2 | $365K | Sell |
3,448
-580
| -14% | -$59.9K | 0.01% | 440 |
|
|
2020
Q1 | $360K | Buy |
4,028
+128
| +3% | +$12.1K | 0.01% | 420 |
|
|
2019
Q4 | $389K | Buy |
3,900
+330
| +9% | +$31.1K | 0.01% | 459 |
|
|
2019
Q3 | $318K | Buy |
+3,570
| New | +$310K | 0.01% | 486 |
|
|
2016
Q1 | – | Sell |
-3,234
| Closed | -$219K | – | 549 |
|
|
2015
Q4 | $219K | Sell |
3,234
-649
| -17% | -$42.5K | 0.01% | 490 |
|
|
2015
Q3 | $247K | Buy |
3,883
+491
| +14% | +$32.3K | 0.01% | 473 |
|
|
2015
Q2 | $216K | Sell |
3,392
-1,251
| -27% | -$85.7K | 0.01% | 504 |
|
|
2015
Q1 | $317K | Buy |
4,643
+254
| +6% | +$17.6K | 0.01% | 432 |
|
|
2014
Q4 | $308K | Buy |
4,389
+51
| +1% | +$3.65K | 0.01% | 451 |
|
|
2014
Q3 | $309K | Hold |
4,338
| – | – | 0.01% | 430 |
|
|
2014
Q2 | $322K | Sell |
4,338
-1,556
| -26% | -$112K | 0.01% | 392 |
|
|
2014
Q1 | $382K | Sell |
5,894
-3
| -0.1% | -$194 | 0.01% | 338 |
|
|
2013
Q4 | $350K | Buy |
5,897
+136
| +2% | +$7.39K | 0.01% | 364 |
|
|
2013
Q3 | $299K | Buy |
5,761
+180
| +3% | +$9.04K | 0.01% | 394 |
|
|
2013
Q2 | $263K | Buy |
+5,581
| New | +$284K | 0.01% | 423 |
|
Other funds holding AZN
EP
IA
Johnson Investment Counsel's AZN Position: Q2 2026 in Review
Johnson Investment Counsel increased its AstraZeneca (AZN) stake by 3.4% in Q2 2026, buying an estimated $27.6K and bringing the position to 4,469 shares worth $847K. The position accounts for 0.01% of the portfolio, ranked #491.
Johnson Investment Counsel first reported a position in AZN in Q2 2013 and has held it in 39 quarters since. The position peaked at $855K in Q4 2025. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Johnson Investment Counsel held 4,469 shares of AstraZeneca worth $847K as of Q2 2026.
- Johnson Investment Counsel bought 147 AstraZeneca shares in Q2 2026, an estimated $27.6K.
- AstraZeneca made up 0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #491 holding.
- Johnson Investment Counsel first reported a position in AstraZeneca in Q2 2013 and has held it in 39 quarters since.
- Johnson Investment Counsel's AstraZeneca position peaked at $855K in Q4 2025.
- 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.